|
Fusion gene ID: 481 |
FusionGeneSummary for ACSL3_PHGDH |
Fusion gene summary |
Fusion gene information | Fusion gene name: ACSL3_PHGDH | Fusion gene ID: 481 | Hgene | Tgene | Gene symbol | ACSL3 | PHGDH | Gene ID | 2181 | 26227 |
Gene name | acyl-CoA synthetase long chain family member 3 | phosphoglycerate dehydrogenase | |
Synonyms | ACS3|FACL3|LACS 3|LACS3|PRO2194 | 3-PGDH|3PGDH|HEL-S-113|NLS|NLS1|PDG|PGAD|PGD|PGDH|PHGDHD|SERA | |
Cytomap | 2q36.1 | 1p12 | |
Type of gene | protein-coding | protein-coding | |
Description | long-chain-fatty-acid--CoA ligase 3fatty-acid-Coenzyme A ligase, long-chain 3lignoceroyl-CoA synthaselong-chain acyl-CoA synthetase 3 | D-3-phosphoglycerate dehydrogenase2-oxoglutarate reductase3-phosphoglycerate dehydrogenaseepididymis secretory protein Li 113malate dehydrogenase | |
Modification date | 20180519 | 20180523 | |
UniProtAcc | O95573 | O43175 | |
Ensembl transtripts involved in fusion gene | ENST00000357430, ENST00000392066, | ENST00000369409, ENST00000369407, ENST00000482968, | |
Fusion gene scores | * DoF score | 6 X 4 X 6=144 | 7 X 4 X 5=140 |
# samples | 7 | 7 | |
** MAII score | log2(7/144*10)=-1.04064198449735 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(7/140*10)=-1 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
Context | PubMed: ACSL3 [Title/Abstract] AND PHGDH [Title/Abstract] AND fusion [Title/Abstract] | ||
Functional or gene categories assigned by FusionGDB annotation |
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
Partner | Gene | GO ID | GO term | PubMed ID |
Hgene | ACSL3 | GO:0044539 | long-chain fatty acid import | 20219900 |
Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
TCGA | RV | LUAD | TCGA-69-7979-01A | ACSL3 | chr2 | 223725976 | + | PHGDH | chr1 | 120263793 | + |
* LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
5UTR-3CDS | ENST00000357430 | ENST00000369409 | ACSL3 | chr2 | 223725976 | + | PHGDH | chr1 | 120263793 | + |
5UTR-3CDS | ENST00000357430 | ENST00000369407 | ACSL3 | chr2 | 223725976 | + | PHGDH | chr1 | 120263793 | + |
5UTR-intron | ENST00000357430 | ENST00000482968 | ACSL3 | chr2 | 223725976 | + | PHGDH | chr1 | 120263793 | + |
5UTR-3CDS | ENST00000392066 | ENST00000369409 | ACSL3 | chr2 | 223725976 | + | PHGDH | chr1 | 120263793 | + |
5UTR-3CDS | ENST00000392066 | ENST00000369407 | ACSL3 | chr2 | 223725976 | + | PHGDH | chr1 | 120263793 | + |
5UTR-intron | ENST00000392066 | ENST00000482968 | ACSL3 | chr2 | 223725976 | + | PHGDH | chr1 | 120263793 | + |
Top |
FusionProtFeatures for ACSL3_PHGDH |
Main function of each fusion partner protein. (from UniProt) |
Hgene | Tgene |
ACSL3 | PHGDH |
Acyl-CoA synthetases (ACSL) activates long-chain fattyacids for both synthesis of cellular lipids, and degradation viabeta-oxidation. ACSL3 mediates hepatic lipogenesis (Bysimilarity). Preferentially uses myristate, laurate, arachidonateand eicosapentaenoate as substrates (By similarity). Has mainly ananabolic role in energy metabolism. Required for the incorporationof fatty acids into phosphatidylcholine, the major phospholipidlocated on the surface of VLDL (very low density lipoproteins).{ECO:0000250, ECO:0000269|PubMed:18003621}. | Catalyzes the reversible oxidation of 3-phospho-D-glycerate to 3-phosphonooxypyruvate, the first step of thephosphorylated L-serine biosynthesis pathway. Also catalyzes thereversible oxidation of 2-hydroxyglutarate to 2-oxoglutarate andthe reversible oxidation of (S)-malate to oxaloacetate.{ECO:0000269|PubMed:11751922, ECO:0000269|PubMed:25406093}. |
Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
- In-frame and retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
- In-frame and not-retained protein feature among the 13 regional features. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for ACSL3_PHGDH |
For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
* Fusion amino acid sequences. |
* Fusion transcript sequences (only coding sequence (CDS) region). |
* Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for ACSL3_PHGDH |
Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
Hgene | Hgene's interactors | Tgene | Tgene's interactors |
ACSL3 | SPG20, TMEM173, NDRG1, SIRT7, APP, ACSL4, MTHFD1, LYN, YES1, HIPK4, MAPK4, PPP6R1, PPP6R2, STAU1, CUL7, OBSL1, CCDC8, GNAT2, NTRK1, TCTN2, TCTN3, EVC2, TMEM17, TMEM216, KIF11, REEP5, KIF20B, TIGD6, SKA1, MCM2, ESRRB, MTMR14, TPTE, IFT140, WDR19, CYLD, TRIM25, TES | PHGDH | MEPCE, UBC, HDAC5, MAPK6, ISG15, FBXO25, CUL3, CUL5, CUL2, CDK2, CAND1, CHMP2B, APP, IK, SAP18, SURF4, NCSTN, SRSF10, TRA2A, SRSF11, SMARCA5, U2AF1, RPS27A, SSRP1, THRAP3, TRIM55, VTN, TCERG1, GTF3C1, VASN, U2AF2, UQCC3, PRKDC, SMU1, SRSF1, ADNP, EEF1A1, STAT1, SRSF5, SON, UTP14A, ECT2, MDC1, TRAF3IP1, FN1, CLN3, CLN5, EGFR, PIAS4, FBXO6, TARDBP, EPN1, ROM1, ITSN1, RPAP3, HUWE1, FUS, CUL7, OBSL1, CCDC8, EZH2, SUZ12, RNF2, BMI1, EPN3, RPS6KB2, ADH5, ASNS, ASS1, CCDC25, GDPGP1, GOT1, GPD1L, HNRNPA1, HSPE1, LDHB, MTHFD1, MYL6, NUDT9, PABPC1, PABPC4, NECAP1, PGAM1, PSPH, VAPA, PLIN3, PROSC, PSAT1, RAD23A, RAD23B, STIP1, TYMS, UBE2N, UBE2NL, UQCRFS1, USP7, NTRK1, XPO1, GAK, SLC33A1, KIF20A, GTSE1, TUBA1C, CRY2, MCM2, SNW1, CDC5L, OTUB1, RC3H1, NFATC1, CDC73, TRIM25, BRCA1, YAP1, HDAC6 |
- Retained PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
- Lost PPIs in in-frame fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
- Retained PPIs, but lost function due to frame-shift fusion. |
Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for ACSL3_PHGDH |
Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
RelatedDiseases for ACSL3_PHGDH |
Diseases associated with fusion partners. (DisGeNet 4.0) |
Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Tgene | PHGDH | C1866174 | Phosphoglycerate Dehydrogenase Deficiency | 3 | CTD_human;UNIPROT |
Tgene | PHGDH | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
Tgene | PHGDH | C0007621 | Neoplastic Cell Transformation | 1 | CTD_human |
Tgene | PHGDH | C0025202 | melanoma | 1 | CTD_human |
Tgene | PHGDH | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
Tgene | PHGDH | C0265218 | Neu-Laxova syndrome | 1 | ORPHANET;UNIPROT |
Tgene | PHGDH | C1458155 | Mammary Neoplasms | 1 | CTD_human |